OncLive interviews Diaceutics at EHA Congress 2019: Retesting for FLT3 Mutation Status in AML

A recent study of FLT3 testing behavior in relapsed acute myeloid leukemia (AML) conducted by experts at Diaceutics has uncovered the need for faster laboratory testing turnaround times (TAT). CTO at Diaceutics, Jordan Clark discussed the findings with OncLiveL1 at this year’s EHA Congress where the abstract was accepted for publication. The abstract analyzes the FLT3 testing behavior in relapsed acute myeloid leukemia (AML) over the course of a year. Read the full abstract hereL2

Link References
1. OncLive
2. here

About Diaceutics
Diaceutics PLC is a leading diagnostic commercialization company for the global pharmaceutical industry. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

Media Contact
Helen Morrogh
Tel: +353 1 215 7675
Email: helen@comit.ie
For more information, visit www.diaceutics.com or follow Diaceutics on Twitter, LinkedIn or Facebook

Latest Blogs

Latest Blogs